ACM
DYN icon

Aster Capital Management’s Dyne Therapeutics DYN Stock Holding History

Aster Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.36K Sell
226
-4,084
-95% -$70.4K ﹤0.01% 750
2025
Q4 		$84.3K Buy
+4,310
New +$81.6K 0.04% 374
2025
Q2 		– Sell
-2,252
Closed -$30.6K – 1181
2025
Q1 		$30.6K Buy
2,252
+2,234
+12,411% +$32K 0.01% 915
2024
Q4 		$424 Buy
+18
New +$532 ﹤0.01% 1041

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Aster Capital Management's DYN Position: Q1 2026 in Review

Aster Capital Management reduced its Dyne Therapeutics (DYN) stake by 95% in Q1 2026, selling an estimated $70.4K and leaving 226 shares worth $2.36K. The position accounts for ﹤0.01% of the portfolio, ranked #750.

Aster Capital Management first reported a position in DYN in Q4 2024 and has held it in 4 quarters since. The position peaked at $84.3K in Q4 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Aster Capital Management held 226 shares of Dyne Therapeutics worth $2.36K as of Q1 2026.
  • Aster Capital Management sold 4,084 Dyne Therapeutics shares in Q1 2026, an estimated $70.4K.
  • Dyne Therapeutics made up ﹤0.01% of Aster Capital Management's portfolio in Q1 2026, its #750 holding.
  • Aster Capital Management first reported a position in Dyne Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Aster Capital Management's Dyne Therapeutics position peaked at $84.3K in Q4 2025.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Aster Capital Management's 13F filing for Q1 2026, filed 13 May 2026.